GlassScriptPhysician profile
Alma S Rigonan
NPI 1083690390
$2,551.06
in general payments reported to CMS, 2019-2025
25 companies · $897 in 2025
The $897 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $190 · 2021: $90.60 · 2022: $109 · 2023: $492 · 2024: $419 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $386.56 | 2022-2025 | |
| Galderma Laboratories, L.P. | $359.01 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $288.56 | 2025 | |
| Amgen INC. | $196.81 | 2024-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $159.55 | 2023-2025 | Dupixent |
| Corium, LLC | $143.38 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $119.79 | 2023-2024 | Vaxneuvance |
| Travere Therapeutics, INC. | $119.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $105.38 | 2019 | |
| Biogen, INC. | $91.91 | 2019 | |
| Phadia US INC. | $90.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $89.78 | 2020 | |
| Alk-Abello, INC | $80.90 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Genentech, INC. | $72.89 | 2020 | |
| Incyte Corporation | $42.30 | 2022-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $33.34 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.48 | 2019-2024 | Bexsero |
| Ars Pharmaceuticals Operations, INC. | $24.93 | 2025 | Neffy |
| Sun Pharmaceutical Industries INC. | $19.62 | 2023 | Ilumya |
| Lilly USA, LLC | $17.53 | 2025 | Ebglyss |
| Pharming Healthcare, INC. | $17.24 | 2025 | Ruconest |
| Pfizer INC. | $15.94 | 2022 | |
| Smith+Nephew, INC. | $15.31 | 2022 | |
| Adlon Therapeutics L.P. | $15.18 | 2020 | |
| Urgo Medical North America, LLC | $12.77 | 2023 | Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alma Rigonan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.